Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 69Neoplasms 20Neoplasm Metastasis 12Brain Neoplasms 4Stomach Neoplasms 2Recurrence 2Osteitis Deformans 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER-2 Gene Amplification 1Glioma 1Glioblastoma 1Diarrhea 1Carcinoma 1Breast Diseases 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × Lapatinib × Clear all
NCT00158782 2017-11-17

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

GlaxoSmithKline

Phase 1 Completed
75 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00516672 2017-11-13

Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
30 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡